The SIRveNIB and SARAH trials, radioembolization vs. sorafenib in advanced HCC patients: reasons for a failure, and perspectives for the future

作     者：Carlo Sposito Vincenzo Mazzaferro 

作者机构：Department of Gastrointestinal Surgery and Liver TransplantationFondazione IRCCS Istituto Nazionale Tumori di MilanoMilanItaly University of MilanMilanItaly 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2018年第7卷第6期

页      面：487-489页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：patients Liver treatment 

摘      要：Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death *** carcinoma(HCC)represents nearly 90%of primary liver cancers,and constitutes a major health problem worldwide(1).When diagnosed at an early stage of the disease,HCC may benefit from potentially curative treatments such as liver resection,liver transplantation or local *** effectiveness of treatment in early and very early stages,most patients are diagnosed or progress to an intermediate or advanced stage,in which treatment options are limited and the prognosis is poor(2).